Skip to main content
. Author manuscript; available in PMC: 2009 Jan 27.
Published in final edited form as: J Med Chem. 2007 Mar 17;50(8):1799–1809. doi: 10.1021/jm0612463

Figure 4.

Figure 4

Quantitative conformationally sampled δ opioid pharmacophore (CSP) models. A) Efficacy model based on the MaxD parameter with the Leu5 residue in 17 and the allylic amino substituent in 18 as the pharmacophoric B group (see Table 4 for original data). B) Efficacy model based on the MaxD parameter with the Leu5 residue in 17 and the Leu5 residue in 18 as the pharmacophoric B group (see Table 5 for original data). C) Affinity model for high efficacy δ opioid ligands with the Leu5 residue in 17 as the pharmacophoric B group (see Table 6 for original data). D) Affinity model for low efficacy δ opioid ligands with the allylic amino substituent in 18 as the pharmacophoric B group (see Table 7 for original data). Affinity models developed using the natural logarithms of experimental values.